Loading...
•
Dec 31, 2019
Enanta Pharmaceuticals Q1 2020 Earnings Report
Reported financial results for the fiscal first quarter, highlighting positive clinical data for EDP-514 and advancements in research and development programs.
Key Takeaways
Enanta Pharmaceuticals reported a decrease in revenue compared to the same quarter last year, with $52.6 million in royalty revenue. Net income was $13.4 million, or $0.65 per diluted share. The company's cash and marketable securities totaled $414.7 million.
Reported positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects.
Initiated Part 2 of the study in nuc-suppressed chronic hepatitis B virus patients.
Advanced research and development programs, with several milestones expected in 2020 from RSV, NASH, and HBV programs.
Cash and marketable securities totaled $414.7 million at December 31, 2019.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta anticipates its current cash, cash equivalents, and marketable securities, along with ongoing royalty revenue, will adequately cover the projected cash needs for its current business and development initiatives in the foreseeable future.